Changes in the Epidemiology of Primary Biliary Cholangitis

Ana Lleo, Francesca Colapietro

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Primary biliary cholangitis (PBC) is considered a model autoimmune disease, characterized by circulating anti-mitochondrial antibodies and a selective autoimmune destruction of intrahepatic cholangiocytes. PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. The pathogenesis is still largely unknown and epidemiologic studies have facilitated the identification of risk factors and the understanding of disease prevalence, geographic variations, heterogeneity, and differences in sex ratio. Recent studies from large international cohorts have better identified prognostic factors suggesting a change in patient management based on risk-stratification tools to identify subgroups at greatest potential benefit from second-line therapies.

Original languageEnglish
Pages (from-to)429-441
Number of pages13
JournalClinics in Liver Disease
Volume22
Issue number3
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Cholangitis
Epidemiology
Sex Ratio
Autoimmune Diseases
Disease Progression
Epidemiologic Studies
Anti-Idiotypic Antibodies
Therapeutics

Keywords

  • Female prevalence
  • Geoepidemiology
  • Personalized medicine
  • Primary biliary cholangitis

ASJC Scopus subject areas

  • Hepatology

Cite this

Changes in the Epidemiology of Primary Biliary Cholangitis. / Lleo, Ana; Colapietro, Francesca.

In: Clinics in Liver Disease, Vol. 22, No. 3, 01.08.2018, p. 429-441.

Research output: Contribution to journalReview article

Lleo, Ana ; Colapietro, Francesca. / Changes in the Epidemiology of Primary Biliary Cholangitis. In: Clinics in Liver Disease. 2018 ; Vol. 22, No. 3. pp. 429-441.
@article{01cb6fa369974ce28375a92f82c72f17,
title = "Changes in the Epidemiology of Primary Biliary Cholangitis",
abstract = "Primary biliary cholangitis (PBC) is considered a model autoimmune disease, characterized by circulating anti-mitochondrial antibodies and a selective autoimmune destruction of intrahepatic cholangiocytes. PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. The pathogenesis is still largely unknown and epidemiologic studies have facilitated the identification of risk factors and the understanding of disease prevalence, geographic variations, heterogeneity, and differences in sex ratio. Recent studies from large international cohorts have better identified prognostic factors suggesting a change in patient management based on risk-stratification tools to identify subgroups at greatest potential benefit from second-line therapies.",
keywords = "Female prevalence, Geoepidemiology, Personalized medicine, Primary biliary cholangitis",
author = "Ana Lleo and Francesca Colapietro",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.cld.2018.03.001",
language = "English",
volume = "22",
pages = "429--441",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Changes in the Epidemiology of Primary Biliary Cholangitis

AU - Lleo, Ana

AU - Colapietro, Francesca

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Primary biliary cholangitis (PBC) is considered a model autoimmune disease, characterized by circulating anti-mitochondrial antibodies and a selective autoimmune destruction of intrahepatic cholangiocytes. PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. The pathogenesis is still largely unknown and epidemiologic studies have facilitated the identification of risk factors and the understanding of disease prevalence, geographic variations, heterogeneity, and differences in sex ratio. Recent studies from large international cohorts have better identified prognostic factors suggesting a change in patient management based on risk-stratification tools to identify subgroups at greatest potential benefit from second-line therapies.

AB - Primary biliary cholangitis (PBC) is considered a model autoimmune disease, characterized by circulating anti-mitochondrial antibodies and a selective autoimmune destruction of intrahepatic cholangiocytes. PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. The pathogenesis is still largely unknown and epidemiologic studies have facilitated the identification of risk factors and the understanding of disease prevalence, geographic variations, heterogeneity, and differences in sex ratio. Recent studies from large international cohorts have better identified prognostic factors suggesting a change in patient management based on risk-stratification tools to identify subgroups at greatest potential benefit from second-line therapies.

KW - Female prevalence

KW - Geoepidemiology

KW - Personalized medicine

KW - Primary biliary cholangitis

UR - http://www.scopus.com/inward/record.url?scp=85049422960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049422960&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2018.03.001

DO - 10.1016/j.cld.2018.03.001

M3 - Review article

VL - 22

SP - 429

EP - 441

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -